First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H (Q33533553)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H |
scientific article |
Statements
1 reference
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H (English)
1 reference
Michael Muscholl
1 reference
Sergei Tjulandin
1 reference
Hans-Gerd Meerpohl
1 reference
Mikhail Lichinitser
1 reference
Alexey G Manikhas
1 reference
Alexandra Coumbos
1 reference
Rolf Kreienberg
1 reference
Andreas du Bois
1 reference
Christian Jackisch
1 reference
Volkmar Müller
1 reference
Matthias Pauschinger
1 reference
Christoph Thomssen
1 reference
Michaela Lehle
1 reference
Olivier Catalani
1 reference
Hans-Joachim Lück
1 reference
22 February 2010
1 reference
1 reference
28
1 reference
1473-1480
1 reference
Identifiers
1 reference
1 reference